{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-015157","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2023-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.592017+00:00","generated_at":"2026-06-20T09:29:59.423580+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Galera Therapeutics regains compliance with Nasdaq MVLS requirement, delisting avoided","bullets":["Received Nasdaq letter confirming compliance with $50M MVLS requirement for continued listing on Nasdaq Global Market.","Hearing before Nasdaq Hearings Panel on Jan 26, 2023 cancelled.","Company had previously been notified of non-compliance in Dec 2022 and appealed delisting.","Common stock (GRTX) will continue trading on Nasdaq Global Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-015157","json":"https://secwatch.observer/filing/0001193125-23-015157.json","markdown":"https://secwatch.observer/filing/0001193125-23-015157.md","text":"https://secwatch.observer/filing/0001193125-23-015157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312523015157/0001193125-23-015157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312523015157/d441370d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T09:29:59.423580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}